title: Coexpression of aPKCλ/ι and IL-6 in prostate cancer tissue correlates with biochemical recurrence.
abstract: Atypical protein kinase C λ/ι (aPKCλ/ι) and interleukin-6 (IL-6) have been implicated in prostate cancer progression, the mechanisms of which have been demonstrated both in vitro and in vivo. However, the clinical significance of the correlation between the expressions of these factors remains to be clarified. In the present study, we report a significant correlation between aPKCλ/ι and IL-6 proteins in prostate cancer tissue by immunohistochemical staining. We evaluated the association of both proteins by analyzing clinicopathological parameters using chi-square test, Kaplan-Meier with log-rank test, and a Cox proportional hazard regression model in univariate and multivariate analyses. The results again showed that the expression of aPKCλ/ι and IL-6 correlates in prostate cancer tissue (P < 0.001). Atypical protein kinase C λ/ι was also found to correlate with the Gleason score (P < 0.001) and with biochemical recurrence after prostatectomy (P = 0.02). Furthermore, aPKCλ/ι correlated with biochemical recurrence in a Kaplan-Meier and log-rank test (P = 0.01) and Cox analysis (P = 0.02 in the univariate analysis, P = 0.02 in the multivariate analysis). The coexpression of aPKCλ/ι and IL-6 also correlated with biochemical recurrence by Kaplan-Meier and log-rank test (P = 0.005) and Cox analysis (P = 0.01 in the univariate analysis, P = 0.03 in the multivariate analysis). These results indicate a strong correlation between aPKCλ/ι and IL-6 in prostate tumors, and that the aPKCλ/ι-IL-6 axis is a reliable prognostic factor for the biochemical recurrence of this cancer.
authors.affiliation: Department of Urology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ishiguro
authors.forename: Kazunori
authors.initials: K
authors.lastname: Akimoto
authors.forename: Yoji
authors.initials: Y
authors.lastname: Nagashima
authors.forename: Eriko
authors.initials: E
authors.lastname: Kagawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Sasaki
authors.forename: Jin-yu
authors.initials: JY
authors.lastname: Sano
authors.forename: Ryo
authors.initials: R
authors.lastname: Takagawa
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Fujinami
authors.forename: Kazunori
authors.initials: K
authors.lastname: Sasaki
authors.forename: Ichiro
authors.initials: I
authors.lastname: Aoki
authors.forename: Shigeo
authors.initials: S
authors.lastname: Ohno
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Kubota
authors.forename: Hiroji
authors.initials: H
authors.lastname: Uemura
mesh_terms: D000328:Adult; D000368:Aged; D006801:Humans; D007150:Immunohistochemistry; D015850:Interleukin-6 / Q000032:analysis*; D007527:Isoenzymes / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000737:chemistry*; D011379:Prognosis; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D011493:Protein Kinase C / Q000032:analysis*; D000099293:Protein Kinase C-lambda
chemical_list: D015850:Interleukin-6; D007527:Isoenzymes; D011493:Protein Kinase C; D000099293:Protein Kinase C-lambda